Sivia Capital Partners LLC Has $768,000 Stake in AbbVie Inc. (NYSE:ABBV)

Sivia Capital Partners LLC increased its stake in AbbVie Inc. (NYSE:ABBV) by 14.3% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 4,218 shares of the company’s stock after purchasing an additional 529 shares during the quarter. AbbVie makes up 0.5% of Sivia Capital Partners LLC’s investment portfolio, making the stock its 28th largest holding. Sivia Capital Partners LLC’s holdings in AbbVie were worth $768,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Vermillion & White Wealth Management Group LLC bought a new stake in shares of AbbVie in the fourth quarter valued at approximately $26,000. IFS Advisors LLC bought a new position in AbbVie during the first quarter worth $36,000. Able Wealth Management LLC acquired a new position in AbbVie during the 4th quarter valued at $33,000. Ables Iannone Moore & Associates Inc. bought a new stake in AbbVie in the 4th quarter valued at $37,000. Finally, Clarity Asset Management Inc. acquired a new stake in AbbVie in the 4th quarter worth $42,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Stock Down 1.3 %

NYSE ABBV opened at $163.84 on Thursday. The stock’s 50 day simple moving average is $164.58 and its 200 day simple moving average is $167.82. The company has a debt-to-equity ratio of 7.93, a current ratio of 0.94 and a quick ratio of 0.83. AbbVie Inc. has a one year low of $132.70 and a one year high of $182.89. The firm has a market cap of $289.32 billion, a PE ratio of 48.62, a price-to-earnings-growth ratio of 2.19 and a beta of 0.64.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, May 3rd. The company reported $2.31 EPS for the quarter, topping the consensus estimate of $2.26 by $0.05. AbbVie had a return on equity of 179.47% and a net margin of 11.02%. The company had revenue of $12.31 billion for the quarter, compared to analysts’ expectations of $11.93 billion. During the same quarter in the prior year, the business earned $2.46 earnings per share. The business’s revenue for the quarter was up .7% on a year-over-year basis. As a group, sell-side analysts forecast that AbbVie Inc. will post 11.27 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Shareholders of record on Monday, July 15th will be paid a $1.55 dividend. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.78%. The ex-dividend date of this dividend is Monday, July 15th. AbbVie’s dividend payout ratio is presently 183.98%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Barclays reduced their target price on shares of AbbVie from $195.00 to $187.00 and set an “overweight” rating for the company in a research note on Monday, April 29th. Piper Sandler reiterated an “overweight” rating and issued a $190.00 price objective on shares of AbbVie in a research report on Tuesday. Guggenheim boosted their price objective on AbbVie from $188.00 to $190.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. Piper Sandler Companies reaffirmed an “overweight” rating and issued a $190.00 target price on shares of AbbVie in a research report on Wednesday. Finally, HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Wednesday, June 5th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $181.07.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.